selpercatinib
Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients
Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.
Foundation Medicine, Eli Lilly Ink CDx Development Deal for Retevmo
The collaboration will initially explore the use of FoundationOne CDx for patients with metastatic rearranged transfection fusion across tumor types.